© 2014 PrimeVax Immuno-Oncology

PrimeVax

Collaborators

CDC

 

The Centers for Disease Control and Prevention (CDC) has awarded PrimeVax with the exclusive use rights of the wild type strain of dengue virus used in the PV-001 therapy. Our dengue strain is unique in that its history shows zero confirmed dengue deaths. This strain was selected by Dr. Duane Gubler, D.Sc., a leading dengue researcher and former director of the CDC Fort Collins, Colorado Infectious Disease Laboratory.  

 

http://www.cdc.gov/